About: Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
Creator	Abbasian, Ladan Davoudi-Monfared, Effat Ghaderkhani, Sara Ghiasvand, Fereshteh Hasannezhad, Malihe Khalili, Hossein Mir, & Mohammadi, Mostafa Nabiee, Morteza Nourian, Anahid Rahmani, Hamid Sadeghi, Setayesh Saeed, Mir Seifi, Arash Yekaninejad, Saeed
source	Medline; PMC
abstract	BACKGROUND: The role of the antiviral therapy in treatment of COVID-19 is still a matter to be investigated. Also efficacy and safety of antiviral regimens were not compared according severity of the disease. In this study the efficacy and safety of hydroxychloroquine plus atazanavir/ritonavir was compared in patients with moderate and severe COVID-19. METHODS: We prospectively evaluated the clinical outcomes of 213 patients with COVID-19 during the hospitalization course and up to 56 days after the hospital discharge. The disease was categorized to moderate and severe based on the severity of pneumonia and peripheral oxygen saturation (SpO2). The patients received the national treatment protocol containing hydroxychloroquine (400 mg BD in first day and then 200 mg BD) plus atazanavir/ritonavir (300/100 mg daily) for 7 days. Main outcomes included discharge rates at day 7, 14 and 28, 28-day mortality, rate of intensive care unit (ICU) admission and intubation, length of hospital and ICU stay and incidence of adverse events. RESULTS: The mean (SD) age of patients was 60(14) years and 53% were male. According to WHO definition, 51.64% and 48.36% of the patients had moderate (SpO2 ≥ 90%) and severe disease (SpO2 < 90%) at baseline, respectively. The discharge rate of the moderate group was significantly higher than the severe group at day 7, 14 and 28 (HR = 0.49; 95% CI: 0.35–0.69, p = < 0.001 at day 7, HR = 0.48; 95% CI: 0.35–0.66, p = < 0.001 at day 14 and HR = 0.49; 95% CI: 0.36–0.67, p = < 0.001at day 28). The 28-day mortality of the severe group was six times higher than the moderate group (HR = 6.00; 95% CI: 2.50–14.44), p = < 0.001). The need of admission in ICU for the severe group and the moderate group was 37.86% and 18.18% of the patients. Length of hospital stay was significantly shorter in the moderate group in comparison with the severe group (5 ± 4 vs. 8 ± 6 days, p < 0.001). Patients in the moderate group experienced the serious adverse events and complications less than the severe group. The discharged patients were followed up to 56 days after discharge. Some of the patients complained of symptoms such as exertional dyspnea, weakness and new-onset hair loss. CONCLUSION: Our study did not support the use of hydroxychloroquine plus atazanavir/ritonavir in patients who had SpO(2) < 90% at the time of hospital admission. SpO2 was the only predictor of clinical outcomes (duration of hospital stay, discharge from the hospital and mortality) in patients treated with hydroxychloroquine plus atazanavir/ritonavir. GRAPHICAL ABSTRACT: [Image: see text]
has issue date	2020-08-28(xsd:dateTime)
bibo:doi	10.1007/s40199-020-00369-2
bibo:pmid	32857301
has license	no-cc
sha1sum (hex)	bb6e60970b11a0ee766a444d55e06bf8b50711de
schema:url	https://doi.org/10.1007/s40199-020-00369-2
resource representing a document's title	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
has PubMed Central identifier	PMC7453126
has PubMed identifier	32857301
schema:publication	Daru
resource representing a document's body	covid:bb6e60970b11a0ee766a444d55e06bf8b50711de#body_text
is schema:about of	named entity 'atazanavir' named entity 'oxygen saturation' named entity 'higher' named entity 'higher' named entity 'severe' named entity 'moderate' named entity 'moderate' named entity 'The' named entity 'TREATMENT' named entity 'BASELINE' named entity 'HOSPITALIZATION' named entity 'RATE' named entity 'COVID-19' named entity '200' named entity 'HOSPITAL DISCHARGE' named entity 'AGE' named entity '0.35' named entity 'RATES' named entity 'DAYS' named entity 'HYDROXYCHLOROQUINE' named entity 'ADMISSION' named entity 'severe' named entity 'According' named entity 'SpO2' named entity 'group' named entity 'The' named entity 'severe' named entity 'patients' named entity 'intensive care unit (ICU)' named entity 'efficacy' named entity 'based' named entity 'SpO2' named entity 'ICU' named entity 'hydroxychloroquine' named entity '95% CI' named entity 'moderate group' named entity 'SpO2' named entity 'national treatment' named entity 'WHO' named entity 'COVID-19' named entity 'oxygen saturation' named entity 'antiviral therapy' named entity 'COVID' named entity 'TUMS' named entity 'AKI' named entity 'ICU' named entity 'SpO2' named entity 'vitamin' named entity 'mortality rate' named entity 'generalized weakness' named entity 'virus' named entity 'administrated' named entity 'intubated' named entity 'pneumonia' named entity '95% CI' named entity 'clinical trials' named entity 'SARS' named entity 'chest CT scan' named entity 'SpO2' named entity 'azithromycin' named entity '0.49' named entity 'Hubei province' named entity 'mortality rate' named entity 'interferon' named entity 'normality test' named entity '0.01' named entity 'serum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software